Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study.
Ruggiero AngeloLuca PotestioSara CacciapuotiLucia GalloTeresa BattistaElisa CamelaGabriella FabbrociniMatteo MegnaPublished in: Dermatologic therapy (2022)